PEspeaks

Feb 11, 2016
There was scant praise from the medical community for the eighth and final budget plan from the Obama administration.
Feb 05, 2016
Pharmaceutical Executive
William Looney identifies three areas where the insular, often maladroit tone of the industry-investor dialogue may be morphing to something more grounded in the larger societal context of healthcare.
Feb 04, 2016
Valeant and Turing's fuzzy explanations of pricing practices to the House Oversight and Government Reform Committee cast a shadow over the broader industry, writes Jill Wechsler.
Feb 02, 2016
As the nation heads towards its first presidential primaries of the 2016 election, pharmaceutical executives should take a few minutes to consider where the leading candidates stand on U.S. Rx policy.
Jan 29, 2016
Pharm Exec Editorial Advisory Board member Cliff Kalb poses some of the pertinent questions he expects the pharma industry will be asking this year.
Jan 20, 2016
Applied Clinical Trials
Telling signs from U.S., Russia, Latin America and UK indicate that governments are squeezing as much value as possible out of their spending on pills and procedures.
Jan 19, 2016
Pharmaceutical Executive
The use of CECs to ensure unbiased reporting of clinical study endpoints has risen sharply. Here's a look at the therapeutic areas where these assessments are most crucial.
Jan 14, 2016
Applied Clinical Trials
Jill Wechsler reports on how FDA is trying to finding a balance between clinical trials large enough to assess all relevant populations and small enough to include deep data on each patient.
Jan 13, 2016
Casey McDonald keeps an eye on the tweets coming from the J.P. Morgan Annual Healthcare Conference, one of the biggest events in the healthcare industry calendar.
Jan 06, 2016
Pharmaceutical Executive
While the 1984 Act has been a boon for lower-cost generics, its goal of incentivizing new drug discovery has failed, write Traci Medford-Rosow and Peter C. Richardson.
lorem ipsum